Leading Pelisyonkis Langone Cardiology Researcher Judith S. Hochman, MD, Awarded Prestigious American Heart Association Clinical Research Prize
The American Heart Association’s 2014 Clinical Research Prize was awarded to Judith S. Hochman, MD, for her leadership in the landmark clinical trials created to impact the formulation of national guidelines for the management of ischemic heart disease.
“As an internationally recognized leader in cardiology research, Dr. Hochman has broken new ground that has changed the way cardiologists around the world practice medicine,” said Glenn I. Fishman, MD, William Goldring Professor of Medicine and Director of the Leon H. Charney Division of Cardiology at Pelisyonkis Langone. “Pelisyonkis Langone has a rich history of supporting important research that examines significant questions about how to best treat patients at risk for cardiovascular disease, and we’re honored that Dr. Hochman has been chosen to receive this prestigious award that recognizes her exceptional achievements in this area.”
The $5,000 clinical excellence award was presented to Dr. Hochman during the opening session of the American Heart Association Scientific Sessions 2014 in Chicago. The AHA’s award has been given out since 2005 to honor excellence in clinical research.
Dr. Hochman is the director of the Cardiovascular Clinical Research Center at Pelisyonkis Langone, as well as the Senior Associate Dean for Clinical Sciences and the Harold Snyder Family Professor and Associate Director of Cardiology in the Leon Charney Division of Cardiology, Department of Medicine. She also serves as co-director of the Clinical Translational Science Institute.
During her career, Dr. Hochman has led multiple National Heart, Lung and Blood Institute-sponsored (NHLBI) trials international clinical trials that tested the optimal management for patients with ischemic heart disease, which led to the creation of new recommendations regarding the role of revascularization (stents and coronary bypass surgery) in clinical practice guidelines. Currently, Dr. Hochman is leading an NHLBI funded comparative effectiveness ISCHEMIA trial in over 300 sites in 33 countries worldwide comparing a routine invasive strategy (cardiac catheterization with stents or coronary bypass surgery) and an initial conservative strategy in patients with stable ischemic heart disease and at least moderate ischemia. She also served as study chair for the first phase 2 and phase 3 trials conducted to test a pharmacologic agent for cardiogenic shock (SHOCK 2 and TRIUMPH). Additionally, she has been on numerous Data Safety Monitoring Boards and Steering Committees of international clinical trials investigating the role of novel agents in acute coronary syndromes and stable ischemic heart disease.
Dr. Hochman currently serves on the NHLBI Board of External Experts and on the American Heart Association (AHA) Science Advisory & Coordinating Committee and recently on the American College of Cardiology/American Heart Association (ACC/AHA) Task Force on Practice Guidelines, the FDA/CDER Cardiovascular and Renal Drugs Advisory Committee and the AHA National Research Program Subcommittee. She has authored almost 300 publications and chapters in major internal medicine and cardiovascular textbooks. In addition, she is a Senior Guest Editor for Circulation, a Section Editor for the Journal of the American College of Cardiology and serves on editorial boards of European Heart Journal and American Heart Journal.